侧脑室注射Orexins对大鼠摄食的影响及机制

目的:探讨侧脑室注射orexins(食欲素)、NPY(神经肽Y)、MCH(黑色素聚集激素)和甘丙肽对大鼠摄食的影响及其机制。方法:将成年雄性Wistar大鼠随机分为对照组、侧脑室注射组和室旁核(PVN)注射组。通过套管将orexin-A、orexin-B、NPY、MCH和甘丙肽分别注射至侧脑室和PVN内,随后测量大鼠食物摄入量,并检测PVN、弓状核(ARC)和VMH内c-fos的表达。结果:与对照组比较,侧脑室注射NPY、MCH和orexin-B 2 h后,大鼠摄食量显著增多(P0.05)。相较于orexin-B和MCH,NPY对摄食的影响更显著(P0.05)。与NS对照组比较,侧脑室注射甘丙肽和orexin-A 1 h后,大鼠摄食量显著增多(P0.05)。与NS对照组比较,侧脑室注射orexin-A可显著增加c-fos在PVN和ARC中的表达,在VMH中效应较弱(P0.05)。与NS对照组比较,PVN注射NPY能显著增加大鼠2 h摄食量(P0.05),PVN注射orexin-A能显著增加大鼠2 h和4 h摄食量(P0.05)。结论:orexins与可促进大鼠摄食,此效应可能通过下丘脑参与摄食调控中枢PVN和ARC而实现的。     

第四脑室注射orexin-A及OX1R拮抗剂对大鼠摄食及自由活动的影响

本文旨在探讨第四脑室注射orexin-A及orexin 1型受体(orexin-1 receptor,OX1R)拮抗剂SB334867对肥胖和正常大鼠摄食和自由活动的影响。采用高脂饲料诱导建立肥胖大鼠模型,分别在肥胖和正常大鼠第四脑室注射不同剂量orexin-A或SB334867,观察光照和黑暗环境下两种大鼠0~4 h摄食量及活动量的变化。结果显示,第四脑室注射不同剂量orexin-A,光照条件下,正常和肥胖大鼠0~4 h摄食量和活动量均较生理盐水对照组明显增加,呈剂量依赖关系(P0.05~0.01);且肥胖大鼠摄食量和活动量显著高于正常大鼠;黑暗条件下,不同剂量的orexin-A对正常和肥胖大鼠摄食量和活动量均没有明显改变(P0.05)。第四脑室注射不同剂量SB334867,光照条件下,正常和肥胖大鼠0~2 h,2~4 h摄食量和活动量均较生理盐水对照组明显减少(P0.05);且肥胖大鼠摄食量和活动量均显著高于正常大鼠;黑暗条件下,正常和肥胖大鼠摄食量和活动量均没有明显改变(P0.05)。以上结果提示,第四脑室周核团可能是orexin-A及OX1R作用靶点之一;光照条件对orexin-A和OX1R生理功能的发挥可能具有重要影响。     

侧脑室注射orexin-A对大鼠昼夜摄食的影响

目的:探讨侧脑室注射orexin-A对大鼠昼夜摄食的影响。方法:将Wistar大鼠随机分组,采用单剂量侧脑室注射和连续侧脑室注射以及外周注射法,分别于日间和夜间给药,测量大鼠24小时内各阶段的摄食量以及相应生化指标。结果:在光照期间,侧脑室微量注射orexin-A,大鼠4小时内摄食量显著增加(P0.05),且呈剂量依赖关系(P0.05)。在夜间初期(18:00)侧脑室注射orexin-A,大鼠食物摄入量无显著差异(P0.05)。但在中午12:00给予侧脑室注射orexin-A,注射后4小时内大鼠摄食量显著高于NS对照组(P0.05)。连续8日给予orexin-A侧脑室注射,可使注射后日间摄食量显著增加(P0.05),而夜间摄食量显著减少(P0.05),但24小时内总的摄食量不变(P0.05)。orexin-A并未改变棕色脂肪组织温度、末梢血糖、血浆瘦素等指标的水平。结论:orexin-A对大鼠摄食的调节具有昼夜节律性。     

大鼠室旁核注射orexin-A对体重的影响

目的:探讨大鼠室旁核(PVN)注射orexin-A对体重的影响。方法:大鼠室旁核(PVN)微量注射orexin-A,用大脑置管埋管、组织化学染色等方法探讨PVN注射orexin-A对其体重的影响。结果:与安慰剂组大鼠相比,PVN注射orexin-A组大鼠体重明显减轻(P0.05),而orexin-A组和安慰剂组摄食量无明显差异(P0.05)。注射结束后6天,orexin-A处理大鼠的体重仍显著低于注射前(P0.05),而安慰剂组大鼠则比注射前显著增重(P0.05)。药物注射可显著降低机体脂肪,但并不特异存在于注射orexin-A或安慰剂的大鼠身上。Orexin-A组和安慰剂组大鼠的肌肉量和脂肪量均显著降低(P0.05),但注射orexin-A的大鼠降低更明显。与安慰剂组相比,orexin-A处理后的摄食转化率显著降低(P0.05)。结论:大鼠室旁核(PVN)注射orexin-A可通过增加活动量产生负能量平衡,引起体重减轻。     

侧脑室微量注射大麻素受体拮抗剂对orexin-A诱导大鼠能量代谢改变的影响及潜在机制研究

目的:探讨大麻素1型受体(CB1)抑制剂利莫那班对下丘脑外侧区(LHA)微量注射orexin-A诱导的小鼠能量代谢及相关行为变化改变的影响。方法:通过侧脑室微量注射(icv)利莫那班,同时LHA微量注射orexin-A,测量小鼠能量代谢、自主运动的变化,杏仁核(CeA)内多巴胺释放能力以及小鼠摄食量的变化。结果:侧脑室微量注射利莫那班可减弱因LHA微量注射orexin-A引起的小鼠能量代谢变化,降低小鼠自主运动,并且减弱小鼠CeA内多巴胺释放能力。注射(icv)利莫那班未改变LHA微量注射orexin-A所诱导的摄食量增多。此外,LHA双侧注射利莫那班可阻断LHA内注射orexin-A对运动活性的促进作用,但不影响小鼠的摄食量。结论:大麻素受体涉及orexin-A诱导的小鼠中脑边缘系统多巴胺系统活化的调控,对能量代谢及自主运动也有影响,但对食物摄入的调节无明显影响。     

急性低血糖应激对大鼠下丘脑orexin-A表达的影响

目的研究胰岛素诱导的急性低血糖应激对大鼠下丘脑增食欲素-A(orexin-A)的表达影响。方法通过皮下注射胰岛素建立急性低血糖大鼠模型。采用免疫组织化学染色方法观察大鼠下丘脑orexin-A和Fos双标情况,并采用ELISA方法对脑脊液中的orexin-A含量进行检测。结果禁食组、低血糖进食组和低血糖禁食组阳性神经元计数明显高于对照组(P0.05),但三组之间计数比较差异无统计学意义(P0.05);Orexin-A/Fos双标细胞率(双标细胞占orexin-A阳性细胞的百分率)在低血糖禁食组最高,与禁食组和低血糖进食组比较差异有统计学意义(P0.05)。ELISA检测结果显示,低血糖禁食组脑脊液中的orexin-A含量显著高于其它三组,差异有统计学意义(P0.05)。结论急性血糖的降低可以增强大鼠下丘脑中orexin-A的表达,而摄食行为可以抑制此调控效应。     

第四脑室注射Orexin-A对大鼠饮食摄取条件性位置偏爱的影响

目的:探讨第四脑室注射orexin-A(OXA)对大鼠饮食摄取条件性位置偏爱的影响。方法:将30只大鼠随机分成3组,即对照组,低剂量组和高剂量组,第四脑室分别注射生理盐水(NS)、orexin-A或orexin-A受体拮抗剂SB334867,观察大鼠按压杠杆获取蔗糖的次数和最高频率的变化。再选择30只大鼠,第四脑室注射orexin-A和SB334867,观察大鼠对高脂饮食(HF)食物的摄入量。另选取30只大鼠第四脑室注射orexin-A或SB334867,将大鼠置于条件位置偏爱箱来检测大鼠对HF条件性位置偏爱的变化。结果:与对照组相比,24小时禁食大鼠,第四脑室注射orexin-A,可显著增加大鼠按压杠杆获取蔗糖的次数和最高频率(P0.05)。而SB334867可显著降低大鼠按压杠杆获取蔗糖次数以及最大频率(P0.05)。第四脑室注射orexin-A,可使大鼠HF摄入量显著增加(P0.05),第四脑室注射SB334867,不影响大鼠HF摄入量,但会抑制普通饮食的摄入(P0.05)。第四脑室注射orexin-A能增强对HF饮食位置偏爱性的表达,注射SB334867后会显著抑制大鼠对HF饮食位置偏爱性的表达(P0.05)。结论:第四脑室注射Orexin-A可影响大鼠摄食行为,增加高脂饮食的摄入量,增强对HF饮食位置偏爱性的表达。     

有氧运动训练和摄食对中华倒刺鲃幼鱼力竭运动后代谢特征的影响

为了探讨有氧运动训练和摄食对中华倒刺鲃（Spinibarbus sinensis）幼鱼力竭运动后代谢特征的影响,在（25±0.5）℃条件下,将120尾实验鱼[体重（21.35±0.05）g,体长（10.21±0.03）cm]随机分成4组,即:对照组、1、2和4 BL/s（体长/秒,body length/s）训练组,分别放置于不同流速下处理8周。随后测定各实验组心脏和鳃指数以及禁食或摄食（轻度麻醉灌喂体重1.5%的饵料）状态下的力竭运动后过量耗氧。结果发现:4 BL/s训练组的心脏和鳃指数都显著高于其他实验组（P < 0.05）;无论摄食与否,3个训练组运动前代谢率都显著高于对照组（P=0.001）,而各实验组过量耗氧均没有显著差异;在禁食状态下,仅4 BL/s训练组的运动代谢峰值和代谢率增量显著高于对照组,而在摄食状态下,3个训练组的运动代谢峰值和代谢率增量均显著高于对照组（P < 0.005）。与禁食组相比,摄食导致各处理组的运动前代谢率显著上升（P < 0.001）,但对运动代谢峰值没有显著影响;另外,摄食对照组代谢率增量和力竭运动后过量耗氧显著低于禁食对照组（P < 0.05）。研究表明:（1）有氧运动训练显著提高了中华倒刺鲃幼鱼的有氧代谢能力,这可能与其呼吸和循环系统功能的改善有关;（2）力竭运动能够诱导出中华倒刺鲃幼鱼的最大有氧代谢率;（3）摄食削弱了中华倒刺鲃幼鱼无氧代谢能力。     

禁食不同时段下丘脑穹窿周区orexin-A的表达

目的探讨禁食不同时段大鼠下丘脑穹窿周区orexin—A的表达及是否与摄食有关。方法观察禁食前后大鼠体重变化,采用免疫组织化学染色法观察禁食不同时段下丘脑穹窿周区orexin-A的表达变化,灰度值测量观察各组orexin—A的染色强度。结果大鼠体重随禁食时间的延长而逐渐降低,各组大鼠禁食前后体重变化有统计学差异（P〈O．01）;Orexin-A主要分布于下丘脑穹窿周区,禁食组orexin—A阳性神经元计数明显多于对照组（P〈O．05）,但不同禁食组间orexin-A阳性神经元计数比较没有统计学差异（P〉O．05）;禁食48h组染色强度最深,与对照组和禁食24h、72h组有明显统计学差异（P〈0．05）。结论禁食可以促进orexin-A的表达,禁食48h应该是一种理想的促进orexin-A活化的刺激方式,orexin-A系统可能参与摄食及能量代谢的调节。     

白藜芦醇甙对糖尿病小鼠心肌损伤的保护作用及机制研究

目的:探讨白藜芦醇甙对小鼠小鼠心肌损伤的影响及其可能的调控机制。方法:采用腹腔注射链脲霉素的方法建立1型糖尿病小鼠模型模型,随机将雄性C57/BL6J的正常小鼠和糖尿病小鼠分为3组(每组18只):对照组、糖尿病组、糖尿病+白藜芦醇甙组。其中糖尿病+白藜芦醇甙组给予白藜芦醇甙7.5 mg/kg/d腹腔注射治疗,对照组和糖尿病组给予同体积盐水腹腔注射。药物治疗12周后,小动物心脏超声检测小鼠的心功能;天狼星红染色观察胶原变化并进一步计算胶原容积分数(collagen volume fraction,CVF);柠檬酸合酶检测试剂盒和ATP生物荧光试剂盒分别检测检测心肌柠檬酸合酶活性和ATP含量;Western blot检测Sirt3和p-AMPK的蛋白表达情况。结果:与对照组相比,糖尿病组LVEDD和LVESD均明显增加(4.823±0.103 mm和3.701±0.121 mm,P0.05),LVEF和LVFS值均明显降低(37.121±4.298%和21.023±2.187%,P0.05),CVF显著增高(20.102±1.155%,P0.05),心肌柠檬酸合酶活性和ATP含量显著降低(5.267±0.202 nmol/g和105±7.638 U/g,P0.05),Sirt3和p-AMPK蛋白表达显著降低(P0.05);与糖尿病组相比,糖尿病+白藜芦醇甙组LVEDD和LVESD均显著降低(4.354±0.113 mm和3.056±0.130 mm,P0.05),LVFS和LVEF值均显著增加(58.435±8.143%和29.071±2.232%,P0.05),CVF显著降低(10.343±0.882%,P0.05),心肌柠檬酸合酶活性和ATP含量显著增加(6.233±0.176 nmol/g和132.7±5.774 U/g,P0.05),Sirt3和p-AMPK蛋白表达显著增加(P0.05)。结论:白藜芦醇甙可改善糖尿病小鼠心肌损伤,其机制可能与白藜芦醇甙激活Sirt3/AMPK信号通路有关。     

Food-induced expression of orexin receptors in rat duodenal mucosa regulates the bicarbonate secretory response to orexin-A

Presence of appetite-regulating peptides orexin-A and orexin-B in mucosal endocrine cells suggests a role in physiological control of the intestine. Our aim was to characterize orexin-induced stimulation of duodenal bicarbonate secretion and modulation of secretory responses and mucosal orexin receptors by overnight food deprivation. Lewis x Dark Agouti rats were anesthetized and proximal duodenum cannulated in situ. Mucosal bicarbonate secretion (pH stat) and mean arterial blood pressure were continuously recorded. Orexin-A was administered intra-arterially close to the duodenum, intraluminally, or into the brain ventricles. Total RNA was extracted from mucosal specimens, reverse transcribed to cDNA and expression of orexin receptors 1 and 2 (OX1 and OX2) measured by quantitative real-time PCR. OX1 protein was measured by Western blot. Intra-arterial orexin-A (60-600 nmol.h(-1).kg(-1)) increased (P < 0.01) the duodenal secretion in fed but not in fasted animals. The OX1 receptor antagonist SB-334867, which was also found to have a partial agonist action, abolished the orexin-induced secretory response but did not affect secretion induced by the muscarinic agonist bethanechol. Atropine, in contrast, inhibited bethanechol but not orexin-induced secretion. Orexin-A infused into the brain ventricles (2-20 nmol.kg(-1).h(-1)) or added to luminal perfusate (1.0-100 nM) did not affect secretion, indicating that orexin-A acts peripherally and at basolateral receptors. Overnight fasting decreased mucosal OX1 and OX2 mRNA expression (P < 0.01) as well as OX1 protein expression (P < 0.05). We conclude that stimulation of secretion by orexin-A may involve both receptor types and is independent of cholinergic pathways. Intestinal OX receptors and secretory responses are markedly related to food intake.     

Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies

Orexin-A and orexin-B are members of a family of newly described orexigenic hypothalamic neuropeptides. Scanty data are available suggesting the involvement of orexins in regulation of the secretion of pituitary hormones and in control of energy homeostasis. Present studies aimed to explain whether orexins affect blood insulin concentration and insulin secretion in the rat. To check this possibility, adult female rats were subcutaneously injected with different doses (1 or 2 nmol) of orexin-A or orexin-B. A bolus administration of orexin-A resulted in an increase in blood insulin (up to min 120) and glucose (60 min after injection) concentration. The higher dose of orexin-B, on the other hand, exerted effect on insulin secretion only at min 60 of experiment and neither doses changed blood glucose level. Only orexin-A stimulated insulin secretion in an in vitro perfusion system of the rat pancreas preparation, while orexin-B was less effective. The results demonstrate that orexins belong to a group of neuropeptides influencing insulin secretion and acting directly on the pancreas. Direct, at least partial, effect of orexin on insulin secretion may be connected with the regulation of metabolism by this peptide.     

Effect of fasting on resting metabolic rate and postprandial metabolic response in Silurus meridionalis

Resting metabolic rate in southern catfish of 2 and 5 day fasting groups were significantly higher than that of the 15 day fasting group ( P  < 0·05). After feeding, peak metabolic rate of specific dynamic action (SDA) of the 15 day fasting group was significantly lower than that of the 2 and 5 day fasting groups ( P  < 0·05). The duration of the SDA of the 15 day fasting group was significantly longer than that of the 2 day fasting group ( P  < 0·05) and the SDA coefficient of the 15 day fasting group was significantly lower than that of the 2 day fasting group ( P  < 0·05).     

Effect of intraperitoneal CCK-8 on food intake and brain orexin-A after 48 h of fasting in the rat

We investigated the interactions of the peripheral satiety peptide cholecystokinin and the brain orexin-A system in the control of food intake. The effect of an intraperitoneal (i.p.) injection of sulfated cholecystokinin octapeptide (in this article called CCK) (5 microg/kg, 4.4 nmol/kg) or of phosphate-buffered saline (PBS, vehicle control) on 48 h fasting-induced feeding and on orexin-A peptide content was analyzed in diverse brain regions innervated by orexin neurons and involved in the control of food intake. Administration of CCK after a 48 h fast reduced fasting-induced hyperphagia (P<0.05). I.p. CCK increased the orexin-A content in the posterior brainstem of 48 h fasted rats by 35% (P<0.05). Fed animals receiving CCK had 48% higher orexin-A levels in the posterior brainstem than fasted rats (P<0.05). In the lateral hypothalamus, fasting decreased orexin-A levels by 50% as compared to fed rats (P<0.05). In the septal nuclei, the combination of fasting and CCK administration reduced orexin-A contents compared to fed PBS and CCK animals by 13% and 17%, respectively (P<0.05). These results suggest a convergence of pathways activated by peripheral CCK and by fasting on the level of orexin-A released in the posterior brainstem and provide evidence for a novel interaction between peripheral satiety signaling and a brain orexigen in the control of food intake.     

Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice.

We have previously shown that hypercapnic chemoreflex in prepro-orexin knockout mice (ORX-KO) is attenuated during wake but not sleep periods. In that study, however, hypercapnic stimulation had been chronically applied for 6 h because of technical difficulty in changing the composition of the inspired gas mixture without distorting the animal's vigilance states. In the present study we examined possible involvement of orexin in acute respiratory chemoreflex during wake periods. Ventilation was recorded together with electroencephalography and electromyography before and after intracerebroventricular administration of orexin or an orexin receptor antagonist, SB-334867. A hypercapnic (5 or 10% CO(2)) or hypoxic (15 or 10% O(2)) gas mixture was introduced into the recording chamber for 5 min. Respiratory parameters were analyzed only for quiet wakefulness. When mice breathed normal room air, orexin-A and orexin-B but not vehicle or SB-334867 increased minute ventilation in both ORX-KO and wild-type (WT) mice. As expected, hypercapnic chemoreflex in vehicle-treated ORX- KO mice (0.22 +/- 0.03 mlxmin(-1)xg(-1)x% CO(2)(-1)) was significantly blunted compared with that in WT mice (0.51 +/- 0.05 mlxmin(-1)xg(-1)x% CO(2)(-1)). Supplementation of orexin-A or -B (3 nmol) partially restored the hypercapnic chemoreflex in ORX-KO mice (0.28 +/- 0.03 mlxmin(-1).g(-1)x% CO(2)(-1) for orexin-A and 0.32 +/- 0.04 mlxmin(-1)xg(-1)x% CO(2)(-1) for orexin-B). In addition, injection of SB-334867 (30 nmol) in WT mice decreased the hypercapnic chemoreflex (0.39 +/- 0.04 mlxmin(-1)xg(-1)x% CO(2)(-1)). On the other hand, hypoxic chemoreflex in vehicle-treated ORX-KO and SB-334867-treated WT mice was not different from that in corresponding controls. Our findings suggest that orexin plays a crucial role in CO(2) sensitivity at least during wake periods in mice.     

Orexin-A通路对胃运动的调控研究

目的:探讨下丘脑外侧核(LHA)-伏隔核(NAcc)orexin-A神经和功能通路构成及该通路对胃运动的影响及潜在机制。方法:将健康成年雄性Wistar大鼠随机分为逆行追踪组和胃运动组:逆行追踪组大鼠采用逆行追踪技术结合免疫荧光组织化学染色法,观察下丘脑外侧核-伏隔核间是否存在orexin-A神经通路;胃运动组大鼠通过在体胃运动研究,观察伏隔核内微量注射不同浓度orexin-A对大鼠胃运动幅度和频率的影响,以及电刺激下丘脑外侧核后,大鼠胃运动的变化及机制。结果:荧光逆行追踪结合荧光免疫组织化学染色结果显示:下丘脑外侧核内有荧光金和orexin-A双重标记的神经元。胃运动研究结果显示:伏隔核内微量注射orexin-A,大鼠胃运动幅度和频率显著增加,并呈现显著剂量依赖关系(P0.05),伏隔核预先微量注射SB-334867,可反转该效应(P0.05)。电刺激下丘脑外侧核,大鼠胃运动幅度和频率显著增强(P0.05)。同样,伏隔核内微量注射SB-334867,再电刺激下丘脑外侧核,电刺激导致的胃运动增强效应显著减弱(P0.05)。结论:下丘脑外侧核-伏隔核存在orexin-A神经和功能通路,该通路可能通过orexin-A受体介导参与胃动力和能量代谢调控。